BPC-157 / TB-500 Blend

Description

Product Specifications

Form: Lyophilized dual-peptide powder

Strength: Add the product-specific BPC-157 / TB-500 strength

Compound Classification: Dual synthetic peptide research formulation

Components: BPC-157 and TB-500

Combined Molecular Formula: Not applicable as a single value because the blend contains two independent peptide molecules

Combined Molecular Weight: Not applicable as a single value

Blend CAS Number: No single CAS number applies to the complete formulation

BPC-157 Component

Peptide Length: 15 amino acid residues

Peptide Classification: Synthetic linear pentadecapeptide research compound

Peptide Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

One-Letter Sequence: GEPPPGKPADDAGLV

N-Terminal Modification: None

C-Terminal Modification: Free carboxyl terminus

Molecular Formula: C₆₂H₉₈N₁₆O₂₂

Molecular Weight: Approximately 1419.5 g/mol

CAS Number: 137525-51-0

PubChem confirms the BPC-157 sequence, formula, molecular weight, and CAS information above.

TB-500 Component

Peptide Length: 7 amino acid residues

Peptide Classification: Synthetic N-terminally acetylated thymosin beta-4-derived peptide fragment

Peptide Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH

One-Letter Sequence: Ac-LKKTETQ-OH

N-Terminal Modification: Acetylated

C-Terminal Modification: Free carboxyl terminus

Molecular Formula: C₃₈H₆₈N₁₀O₁₄ for the commonly referenced Ac-LKKTETQ form

Molecular Weight: Approximately 889.0 g/mol

CAS Number: 885340-08-9, where assigned to the Ac-LKKTETQ TB-500 fragment

Cayman Chemical identifies TB-500 acetate as Ac-LKKTETQ-OH with molecular formula C₃₈H₆₈N₁₀O₁₄ and molecular weight approximately 889.0, while WADA documentation identifies TB-500 as N-Ac-LKKTETQ.

Blend Specifications

Purity: Individual peptide purity should be ≥99%, where confirmed through batch-specific HPLC analysis

Appearance: White to off-white lyophilized peptide powder

Intended Use: Laboratory research and analytical applications only

Research Applications

Analytical characterization using HPLC, UPLC, and LC-MS workflows

Simultaneous identification of BPC-157 and TB-500 within a multi-peptide formulation

Chromatographic separation and quantification of individual blend components

Comparative analysis of linear and N-terminally acetylated peptide structures

Structure-activity assessment of distinct peptide sequences

Investigation of peptide-mediated molecular interactions under controlled conditions

Evaluation of component identity, purity, molecular weight, and structural integrity

Assessment of formulation homogeneity and batch-to-batch consistency

Evaluation of component compatibility within a dual-peptide formulation

Stability profiling under defined temperature, pH, buffer, and storage conditions

Quality Documentation

A batch-specific Certificate of Analysis and applicable analytical documentation should be available for each lot. Documentation should independently verify the identity, amount, and purity of both BPC-157 and TB-500 together with formulation ratio, molecular mass, counterion status, and batch information.

Particular attention should be given to the identity assigned to TB-500. The designation has not been used consistently across all commercial and scientific contexts. WADA analytical documentation specifically identifies TB-500 as N-acetyl-LKKTETQ, while some commercial materials may use the name for other thymosin beta-4-related preparations.

A single molecular formula, molecular weight, or CAS number should therefore not be assigned to the complete BPC-157 / TB-500 blend. Batch-specific HPLC and mass-spectrometric documentation should be used as the final reference for component identity and analytical specifications.

For Laboratory Research Use Only

This product is intended exclusively for controlled laboratory and in vitro research. Not for human or veterinary use. Not for diagnostic, therapeutic, clinical, cosmetic, or household applications.